The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - eFFECTOR Therapeutics
Stock and Other Ownership Interests - eFFECTOR Therapeutics
Patents, Royalties, Other Intellectual Property - eFFECTOR Therapeutics
A phase II, open label, randomized, noncomparative study of eFT508 (tomivosertib) alone or in combination with avelumab in subjects with relapsed/refractory microsatellite stable colorectal cancer (MSS CRC).
 
Joleen Marie Hubbard
Consulting or Advisory Role - Genentech/Roche (Inst)
Research Funding - Bayer (Inst); Boston Biomedical (Inst); eFFECTOR Therapeutics (Inst); Merck (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst); Treos Bio (Inst)
 
Manish R. Patel
Consulting or Advisory Role - Pfizer/EMD Serono; Pharmacyclics/Janssen
Speakers' Bureau - Celgene; Exelixis; Genentech/Roche; Taiho Pharmaceutical
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Bayer (Inst); Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Celgene; Celgene (Inst); Genentech/Roche; Glenmark; Immuneering; Imugene; Incyte (Inst); Ipsen (Inst); Lilly; Lilly (Inst); Merck (Inst); NCCN; Pfizer; Regeneron; Roche/Genentech (Inst); Sirtex Medical; Taiho Pharmaceutical
Research Funding - NCCN; NCI; Oncolytics
Other Relationship - ARMO BioSciences; Exelixis; Exelixis; Merck; Polaris; Sillajen
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Consulting or Advisory Role - EMD Serono; Fujifilm (Inst)
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BeiGene (Inst); Biothera (Inst); Celgene (Inst); Celldex (Inst); Celldex (Inst); Celldex (Inst); Celldex (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Jounce Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Lilly; Loxo (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Precision Oncology (Inst); Regeneron (Inst); Rgenix (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tocagen (Inst); Vegenics (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute
 
Bradley L. Freilich
Employment - HCA Healthcare
Leadership - HCA Healthcare; HCA Healthcare (I)
Stock and Other Ownership Interests - HCA Healthcare; HCA Healthcare (I)
Honoraria - Gilead Sciences; Intercept Pharmaceuticals
Research Funding - HCA Healthcare
 
Arvind Dasari
Consulting or Advisory Role - Abbvie/Stemcentrx; Ipsen; Lexicon; Novartis; Voluntis
Research Funding - eFFECTOR Therapeutics; Eisai; Novartis
 
Benjamin T Knisely
Employment - eFFECTOR Therapeutics; La Jolla Pharma
Stock and Other Ownership Interests - eFFECTOR Therapeutics; La Jolla Pharma
 
Marlisa Anderson
No Relationships to Disclose
 
Gary Gene Chiang
Employment - eFFECTOR Therapeutics
Stock and Other Ownership Interests - Abbvie
Research Funding - eFFECTOR Therapeutics
Travel, Accommodations, Expenses - eFFECTOR Therapeutics
 
Kevin R Webster
No Relationships to Disclose
 
Sam Sperry
Employment - eFFECTOR Therapeutics; Inception Sciences (I)
Stock and Other Ownership Interests - Vertex
Patents, Royalties, Other Intellectual Property - eFFECTOR Therapeutics
 
Jeremy Barton
Employment - eFFECTOR Therapeutics
Leadership - eFFECTOR Therapeutics
Stock and Other Ownership Interests - eFFECTOR Therapeutics
 
Johanna C. Bendell
Consulting or Advisory Role - Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cerulean Pharma (Inst); Continuum Clinical (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); Ipsen (Inst); Janssen (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Moderna Therapeutics (Inst); Molecular Partners (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Phoenix Biotech (Inst); Prelude Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tanabe Research (Inst); TD2 (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tolero Pharmaceuticals (Inst); Torque (Inst)
Research Funding - Abbott/AbbVie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Agios (Inst); Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); ImClone Systems (Inst); Incyte (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Jacobio (Inst); Janssen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Pieris Pharmaceuticals (Inst); Prelude Therapeutics (Inst); Rgenix (Inst); Sanofi (Inst); Sierra Oncology (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Torque (Inst); TRACON Pharma (Inst); Tyrogenex (Inst); Unum Therapeutics (Inst); Vyriad (Inst)
Travel, Accommodations, Expenses - ARMO BioSciences; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; FORMA Therapeutics; Gilead Sciences; Ipsen; Lilly; MedImmune; Merck; Novartis; OncoMed; Roche/Genentech; Taiho Pharmaceutical